Charles River Laboratories International, Inc. (CRL)
NYSE: CRL · Real-Time Price · USD
155.55
-2.51 (-1.59%)
At close: Mar 28, 2025, 4:00 PM
154.36
-1.19 (-0.77%)
Pre-market: Mar 31, 2025, 7:53 AM EDT
CRL Revenue
In the year 2024, Charles River Laboratories International had annual revenue of $4.05B, down -1.92%. Charles River Laboratories International had revenue of $1.00B in the quarter ending December 28, 2024, a decrease of -1.08%.
Revenue (ttm)
$4.05B
Revenue Growth
-1.92%
P/S Ratio
1.97
Revenue / Employee
$201,492
Employees
20,100
Market Cap
7.96B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 28, 2024 | 4.05B | -79.42M | -1.92% |
| Dec 30, 2023 | 4.13B | 153.35M | 3.86% |
| Dec 31, 2022 | 3.98B | 435.90M | 12.31% |
| Dec 25, 2021 | 3.54B | 616.23M | 21.08% |
| Dec 26, 2020 | 2.92B | 302.71M | 11.55% |
| Dec 28, 2019 | Pro | Pro | Pro |
| Dec 29, 2018 | Pro | Pro | Pro |
| Dec 30, 2017 | Pro | Pro | Pro |
| Dec 31, 2016 | Pro | Pro | Pro |
| Dec 26, 2015 | Pro | Pro | Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 400.28B |
| Johnson & Johnson | 88.82B |
| Merck & Co. | 64.17B |
| AbbVie | 56.33B |
| AstraZeneca | 54.07B |
| Novartis AG | 51.72B |
| Eli Lilly and Company | 45.04B |
| Thermo Fisher Scientific | 42.88B |
CRL News
- 5 days ago - Charles River and Valo Health Identify a Potential Therapeutic for Lupus Using Logica®, an AI-Powered Drug Discovery Platform - Business Wire
- 19 days ago - Charles River Laboratories to Present at Barclays Global Healthcare Conference - Business Wire
- 27 days ago - FairJourney Biologics Acquires Charles River Laboratories South San Francisco Facility - Business Wire
- 4 weeks ago - Charles River Announces Agreement with Singapore General Hospital - Business Wire
- 5 weeks ago - Analyst Sees Charles River As Preclinical Leader But Maintains Neutral Stance - Benzinga
- 5 weeks ago - Charles River Laboratories International, Inc. (CRL) Q4 2024 Earnings Call Transcript - Seeking Alpha
- 5 weeks ago - Charles River beats quarterly estimates on stable demand for drug development services - Reuters
- 5 weeks ago - Charles River Laboratories Announces Fourth-Quarter and Full-Year 2024 Results and Provides 2025 Guidance - Business Wire